Table 5 Univariate and multivariate Cox hazards model analyses for mortality during the 30-month follow-up period in the IPF patients

 Male

0.60 (0.17–2.78)

0.48

 Female

1.64 (0.35–5.75)

0.48

Age

1.09 (1.001–1.20)^b

0.04

1.04 (0.95–1.16)

0.31

% predicted VC

0.98 (0.95–1.01)^b

0.31

Emphysematous lesion detected by CT

2.20 (0.33–8.06)

0.35

Rate (%) of decline in VC per 6 months

1.04 (0.98–1.09)^b

0.11

KL-6

0.99 (0.99–1.00)^b

0.85

SP-D

1.00 (0.99–1.00)^b

0.41

LDH

0.99 (0.97–1.00)^b

0.23

miR-21-5p (copies/SI)^a (per one copy/SI)

1.15 (1.04–1.25)^b

0.007

1.12 (1.003–1.24)

0.04

CD9-positive EVs (×10⁶ SI/mL) (per 1 ×10⁶ SI/mL)

0.89 (0.75–1.02)^b

0.10